NextCell Pharma AB, develops ProTrans, a drug candidate consisting of mesenchymal stem cells for the treatment of autoimmune and inflammatory diseases as well as for potential use in kidney transplants. ProTrans consists of selected mesenchymal stem cells derived from the umbilical cord tissue and is developed using NextCell Pharma AB’s proprietary selection algorithm. The company is currently running a phase I/II trial with ProTrans for the treatment of patients with type 1-diabetes.
In addition, the company has a service called Cellaviva, Sweden’s first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. The NextCell Pharma headquarters and laboratories are located in the Karolinska Science Park in Huddinge.